|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADD1 |
Gene summary for ADD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADD1 | Gene ID | 118 |
| Gene name | adducin 1 | |
| Gene Alias | ADDA | |
| Cytomap | 4p16.3 | |
| Gene Type | protein-coding | GO ID | GO:0001885 | UniProtAcc | P35611 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 118 | ADD1 | P79T-E | Human | Esophagus | ESCC | 1.65e-19 | 3.73e-01 | 0.1154 |
| 118 | ADD1 | P80T-E | Human | Esophagus | ESCC | 1.08e-18 | 7.43e-01 | 0.155 |
| 118 | ADD1 | P82T-E | Human | Esophagus | ESCC | 1.09e-20 | 6.74e-01 | 0.1072 |
| 118 | ADD1 | P83T-E | Human | Esophagus | ESCC | 1.02e-25 | 5.21e-01 | 0.1738 |
| 118 | ADD1 | P84T-E | Human | Esophagus | ESCC | 4.94e-07 | 2.28e-01 | 0.0933 |
| 118 | ADD1 | P89T-E | Human | Esophagus | ESCC | 1.62e-02 | 5.50e-01 | 0.1752 |
| 118 | ADD1 | P91T-E | Human | Esophagus | ESCC | 3.44e-09 | 9.37e-01 | 0.1828 |
| 118 | ADD1 | P104T-E | Human | Esophagus | ESCC | 1.32e-11 | 2.50e-01 | 0.0931 |
| 118 | ADD1 | P107T-E | Human | Esophagus | ESCC | 2.89e-17 | 5.46e-01 | 0.171 |
| 118 | ADD1 | P126T-E | Human | Esophagus | ESCC | 2.40e-04 | 6.10e-01 | 0.1125 |
| 118 | ADD1 | P127T-E | Human | Esophagus | ESCC | 9.42e-29 | 2.46e-02 | 0.0826 |
| 118 | ADD1 | P128T-E | Human | Esophagus | ESCC | 7.43e-26 | 7.20e-01 | 0.1241 |
| 118 | ADD1 | P130T-E | Human | Esophagus | ESCC | 7.78e-28 | 5.98e-01 | 0.1676 |
| 118 | ADD1 | S43 | Human | Liver | Cirrhotic | 2.80e-02 | -1.90e-02 | -0.0187 |
| 118 | ADD1 | HCC1_Meng | Human | Liver | HCC | 4.30e-32 | -9.00e-02 | 0.0246 |
| 118 | ADD1 | HCC2_Meng | Human | Liver | HCC | 2.61e-39 | 1.64e-01 | 0.0107 |
| 118 | ADD1 | cirrhotic1 | Human | Liver | Cirrhotic | 7.59e-04 | 4.47e-02 | 0.0202 |
| 118 | ADD1 | cirrhotic2 | Human | Liver | Cirrhotic | 5.34e-07 | 7.20e-02 | 0.0201 |
| 118 | ADD1 | HCC1 | Human | Liver | HCC | 5.54e-19 | 5.18e+00 | 0.5336 |
| 118 | ADD1 | HCC2 | Human | Liver | HCC | 1.13e-10 | 3.71e+00 | 0.5341 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
| GO:0032535 | Colorectum | AD | regulation of cellular component size | 142/3918 | 383/18723 | 1.74e-13 | 3.41e-11 | 142 |
| GO:1902903 | Colorectum | AD | regulation of supramolecular fiber organization | 139/3918 | 383/18723 | 2.01e-12 | 3.19e-10 | 139 |
| GO:0032970 | Colorectum | AD | regulation of actin filament-based process | 142/3918 | 397/18723 | 4.05e-12 | 5.90e-10 | 142 |
| GO:0110053 | Colorectum | AD | regulation of actin filament organization | 108/3918 | 278/18723 | 5.02e-12 | 6.98e-10 | 108 |
| GO:0008154 | Colorectum | AD | actin polymerization or depolymerization | 90/3918 | 218/18723 | 6.14e-12 | 8.23e-10 | 90 |
| GO:0032271 | Colorectum | AD | regulation of protein polymerization | 94/3918 | 233/18723 | 1.01e-11 | 1.29e-09 | 94 |
| GO:0030041 | Colorectum | AD | actin filament polymerization | 81/3918 | 191/18723 | 1.35e-11 | 1.69e-09 | 81 |
| GO:0051258 | Colorectum | AD | protein polymerization | 112/3918 | 297/18723 | 1.85e-11 | 2.27e-09 | 112 |
| GO:0043254 | Colorectum | AD | regulation of protein-containing complex assembly | 148/3918 | 428/18723 | 2.64e-11 | 3.18e-09 | 148 |
| GO:0002064 | Colorectum | AD | epithelial cell development | 89/3918 | 220/18723 | 2.98e-11 | 3.52e-09 | 89 |
| GO:0008064 | Colorectum | AD | regulation of actin polymerization or depolymerization | 79/3918 | 188/18723 | 4.17e-11 | 4.74e-09 | 79 |
| GO:0030833 | Colorectum | AD | regulation of actin filament polymerization | 74/3918 | 172/18723 | 4.50e-11 | 5.03e-09 | 74 |
| GO:0030832 | Colorectum | AD | regulation of actin filament length | 79/3918 | 189/18723 | 5.71e-11 | 6.27e-09 | 79 |
| GO:0032956 | Colorectum | AD | regulation of actin cytoskeleton organization | 127/3918 | 358/18723 | 1.03e-10 | 1.04e-08 | 127 |
| GO:0045216 | Colorectum | AD | cell-cell junction organization | 80/3918 | 200/18723 | 5.57e-10 | 4.58e-08 | 80 |
| GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
| GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
| GO:0032984 | Colorectum | AD | protein-containing complex disassembly | 81/3918 | 224/18723 | 9.41e-08 | 4.65e-06 | 81 |
| GO:0010639 | Colorectum | AD | negative regulation of organelle organization | 114/3918 | 348/18723 | 1.41e-07 | 6.49e-06 | 114 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADD1 | SNV | Missense_Mutation | c.1276N>A | p.Asp426Asn | p.D426N | P35611 | protein_coding | deleterious(0) | possibly_damaging(0.452) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| ADD1 | SNV | Missense_Mutation | rs370911124 | c.76N>A | p.Asp26Asn | p.D26N | P35611 | protein_coding | deleterious(0) | possibly_damaging(0.761) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| ADD1 | SNV | Missense_Mutation | novel | c.1901N>C | p.Asp634Ala | p.D634A | P35611 | protein_coding | tolerated(0.2) | benign(0.075) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
| ADD1 | SNV | Missense_Mutation | rs760404515 | c.1924N>T | p.Pro642Ser | p.P642S | P35611 | protein_coding | tolerated(0.1) | probably_damaging(0.999) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| ADD1 | SNV | Missense_Mutation | novel | c.2224N>T | p.Pro742Ser | p.P742S | P35611 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| ADD1 | insertion | In_Frame_Ins | novel | c.1902_1903insAGGGAGGAGGAATCTAGAGAGGCAGTCTGGCTA | p.Asp634_Gln635insArgGluGluGluSerArgGluAlaValTrpLeu | p.D634_Q635insREEESREAVWL | P35611 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| ADD1 | insertion | Nonsense_Mutation | novel | c.1925_1926insTTAAACTTCTGAAATAAAGACAGAGA | p.Pro643Ter | p.P643* | P35611 | protein_coding | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| ADD1 | deletion | Frame_Shift_Del | novel | c.533delN | p.Glu178AspfsTer15 | p.E178Dfs*15 | P35611 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ADD1 | SNV | Missense_Mutation | novel | c.1145G>A | p.Arg382Gln | p.R382Q | P35611 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ADD1 | SNV | Missense_Mutation | c.85N>C | p.Asp29His | p.D29H | P35611 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 118 | ADD1 | KINASE | bumetanide | BUMETANIDE | 20877298 | |
| 118 | ADD1 | KINASE | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | 19057513,14553962,18591455,11882573,9149697,12623934,10523341 | |
| 118 | ADD1 | KINASE | furosemide | FUROSEMIDE | 20877298,21692745 | |
| 118 | ADD1 | KINASE | torasemide | TORSEMIDE | 20877298 | |
| 118 | ADD1 | KINASE | spironolactone | SPIRONOLACTONE | 21692745 | |
| 118 | ADD1 | KINASE | diuretics | 17189961,11926892 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |